TYK MEDICINES-B (02410) Subscription Agreement for Issuance of H Shares Under General Mandate Lapses

TYK MEDICINES-B (02410) announced that in relation to the licensing and collaboration with Qilu and the proposed issuance of 63,222,700 H Shares to the subscriber. The subscription is subject to the fulfillment or waiver of the conditions precedent under the subscription agreement. If the conditions for the subscription are not fulfilled or waived by the amended long stop date (i.e., September 20, 2026), the subscription agreement will be terminated. As at the date of this announcement, certain conditions precedent under the subscription agreement have not been fulfilled or waived. After careful consideration of the current market conditions and recent changes in the share price, the Company and Qilu have mutually agreed not to further extend the amended long stop date, and the subscription agreement will therefore lapse in accordance with its terms upon the end of the amended long stop date (i.e., September 20, 2026). Thereafter, save for any antecedent breach, neither party shall have any obligations or liabilities under the subscription agreement. With respect to the licensing and collaboration agreement and the supply and commercialization agreement as disclosed in the announcement, Qilu and the Company will continue to comply with their respective obligations under such agreements. The Board considers that the lapse of the subscription agreement will not have any material adverse impact on the business operations and financial position of the Group. Both parties remain willing to cooperate on the share issuance and subscription, and the specific details are still under negotiation.